Sanhuang decoction combined with neoadjuvant chemotherapy for triple negative breast cancer

Updated: Jun 3

Title: Study of Sanhuang decoction combined with pirarubicin, docetaxel and cyclophosphamide for neoadjuvant chemotherapy in the treatment of triple negative breast cancer.


Objective: To explore the clinical efficacy of a Chinese herb medicine formular, Sanhuang decoction, combined with pirubicin, docetaxel, and cyclophosphamide for neoadjuvant chemotherapy in the treatment of triple-negative breast cancer(TNBC).


Methods: A total of 148 TNBC patients were randomly divided into control group and study group,74 cases in each group. The control group was given pirarubicin, docetaxel and cyclophosphamide for neoadjuvant chemotherapy, while study group was treated with Sanhuang decoction (Huangqi, Jianghuang, Dahuang) on basis of control group. The clinical curative effect after treatment, overall survival(OS)of 2-year follow-up, progression-free survival(PFS) and Kamofsky scores in both groups were recorded. The levels of immune indexes(CD3+,CD4+,CD8+,CD4+/CD8+)in both groups before and after treatment were detected. The occurrence of adverse reactions during treatment in both groups was recorded.


Results: After treatment, total remission rate and total control rate were higher in study group than control group(P<0.05).After treatment, levels of CD3+,CD4+ and CD4+/CD8+were higher in study group than control group(P<0.05),while CD8+ level was lower in study group(P<0.05). Kamofsky score was higher in study group than control group(P<0.05).During treatment, incidence of adverse reactions was lower in study group than control group(P<0.05).


Conclusion: Sanhuang decoction combined with pirarubicin, docetaxel and cyclophosphamide for neoadjuvant chemotherapy in treatment of TNBC can improve clinical curative effect, enhance immunity, and improve prognosis, with higher medication safety.


Keywrods: Triple negative breast cancer; Sanhuang decoction; Pirarubicin; Docetaxel; Cyclophosphamide; Neoadjuvant chemotherapy.


Reference: http://www.sxzyxzz.com/oa/DArticle.aspx?type=view&id=20211010 , DOI:10.3969/j.issn.1000-7369.2020.10.010 【Article in Chinese】


8 views0 comments